We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Multi-ingredient Nutrition Supplement in Older Adults

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2013 by Brendan Egan, University College Dublin.
Recruitment status was:  Not yet recruiting
ClinicalTrials.gov Identifier:
First Posted: December 5, 2013
Last Update Posted: December 5, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Smartfish AS
Information provided by (Responsible Party):
Brendan Egan, University College Dublin

The aims of the present study are:

i. To conduct a population study of body composition, muscle function and ability to undertake activities of daily living in elderly Irish individuals

ii. To investigate the effect of a six month period of nutrition supplement support on lean tissue mass, and muscle and cognitive function in individuals aged 70 to 80 years.

Condition Intervention
Physical Disability Dietary Supplement: Supplement Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Effect of a Nutrition Supplement Containing Fish Oil, Whey Protein, Vitamin D, and Resveratrol, on Muscular and Cognitive Function in Older Adults

Resource links provided by NLM:

Further study details as provided by Brendan Egan, University College Dublin:

Primary Outcome Measures:
  • Total and appendicular muscle mass [ Time Frame: Change from Baseline at day 84 & day 168 ]
    By means of measurement of lean body mass using dual-energy X-ray absorptiometry (DXA)

Secondary Outcome Measures:
  • Lower extremity physical function [ Time Frame: Change from Baseline at day 84 & day 168 ]
    By means of score ranging from 0 (worst performance) to 12 (best performance) achieved on the Short Performance Battery Test (Guralnik et al J Gerontol. 1994 49(2):M85-94)

  • Cognitive performance [ Time Frame: Change from Baseline at day 84 & day 168 ]
    By means of performances in the following battery: Timed Up and Go test, Trail Making Test (TMT) part A and B, Auditory Verbal Learning Test, Stroop Colour-Word Test, Verbal Fluency, Forward and Backward Digit Spans, and Cognitive Failures Questionnaire

Estimated Enrollment: 50
Study Start Date: January 2014
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Supplement

Liquid nutrient support (quantity 200 mL per day; energy 200 kcal per day):

Carbohydrate 28.5 g

Protein 8 g as Whey Protein Isolate

ω-3 PUFA 3000 mg, as DHA 1500mg, as EPA 1500mg

Vitamin D3 10 μg

Resveratrol 150 mg

Dietary Supplement: Supplement
Placebo Comparator: Control

Placebo control

Liquid nutrient support

Quantity 200 mL per day - fruit juice only i,e. in absence of bioactives present in the "supplement" (whey protein, omega 3, vitamin D and resveratrol).

Dietary Supplement: Placebo

  Show Detailed Description


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   70 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • ≥ 70 years of age
  • Medically stable, according to Greig et al. (1994)
  • BMI between 20 and 30 kg/m2
  • Sedentary lifestyle, defined by ≤125 min/week of activity on the CHAMPS-18 questionnaire;

Exclusion criteria:

  • Not medically stable by Greig criteria, and the medical history details in the ethics form
  • Conducting an active lifestyle
  • Skeletal muscle index (SMI) of ≥ 6.75 kg/m2 for women or ≥ 10.75 kg/m2 for men according to Janssen et al. (2003)
  • Cognitive impairment expressed as mini mental state examination (MMSE) score ≤ 23.
  • Current or recent (8 wk) use of fish-oil supplement intake
  • Current or recent (8 wk) use of proteins, vitamins or other supplements interfering the metabolic scope
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02001831

Contact: Brendan Egan, PhD brendan.egan@ucd.ie

UCD Institute for Sport and Health Active, not recruiting
Dublin, Ireland, Dublin 4
Sponsors and Collaborators
University College Dublin
Smartfish AS
Study Director: Giuseppe De Vito, MD, PhD School of Public Health, Physiotherapy and Population Sciences. University College Dublin
  More Information

Responsible Party: Brendan Egan, Lecturer in Sport and Exercise Science, University College Dublin
ClinicalTrials.gov Identifier: NCT02001831     History of Changes
Other Study ID Numbers: SMF-3000
First Submitted: August 15, 2013
First Posted: December 5, 2013
Last Update Posted: December 5, 2013
Last Verified: November 2013

Keywords provided by Brendan Egan, University College Dublin:
Skeletal muscle

Additional relevant MeSH terms:
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Antimutagenic Agents
Anticarcinogenic Agents